Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 5/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CKS1B | P61024 | 1/20 | 0.39 |
| ▸ | SKP1 | P63208 | 1/20 | 0.39 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | RET | P07949 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17374360 | 1.00 | KMT2A (0.42) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL17874277 | 0.84 | PSMB8 (0.35) | KMT2AL3MBTL1 | |
| SCHEMBL29992631 | 0.83 | KMT2A (0.44) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL26817401 | 0.81 | KMT2A (0.45) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL30670681 | 0.81 | KMT2A (0.45) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL17374168 | 0.80 | KMT2A (0.48) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL17374170 | 0.80 | KMT2A (0.48) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL17374195 | 0.80 | KMT2A (0.46) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL19239553 | 0.80 | KMT2A (0.48) | KMT2AL3MBTL1JAK1JAK2KDM1A | |
| SCHEMBL17374313 | 0.80 | KMT2A (0.46) | KMT2AL3MBTL1JAK1JAK2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| EP-3157917-B1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2020-03-18 | — | — | EP | disclosed |
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2019-10-10 | — | — | US | disclosed |
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS, INC. | 2019-01-24 | — | — | US | disclosed |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| EP-3157917-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | Proteostasis Therapeutics, Inc. (US) | 2017-04-26 | — | — | EP | disclosed |
| WO-2016105468-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2015196071-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308960-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | KMT2A 4776/4885L3MBTL1 3551/4885JAK1 4801/4885 |
| US-10344023-B2 | Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis | CFTR, ABCC5, ABCD3 | KMT2A 3963/4885L3MBTL1 1740/4885JAK1 4172/4885 |
| US-20170362214-A1 | DERIVATIVES OF 3-HETEROARYLISOXAZOL-5-CARBOXYLIC AMIDE USEFUL FOR THE TREATMENT OF INTER ALIA CYSTIC FIBROSIS | CFTR, ABCC5, ABCD3 | KMT2A 3963/4885L3MBTL1 1740/4885JAK1 4172/4885 |
| US-10174014-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | KMT2A 4776/4885L3MBTL1 3551/4885JAK1 4801/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | KMT2A 4776/4885L3MBTL1 3551/4885JAK1 4801/4885 |
| US-20190022071-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | KMT2A 4017/4885L3MBTL1 3802/4885JAK1 3557/4885 |
| US-20180147187-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCC2, ABCB4 | KMT2A 4796/4885L3MBTL1 4333/4885JAK1 4713/4885 |
| US-10738040-B2 | Compounds, compositions, and methods for increasing CFTR activity | CFTR, ABCB4, SCNN1B | KMT2A 4776/4885L3MBTL1 3551/4885JAK1 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.